FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892063324> ?p ?o ?g. }

• W2892063324 endingPage "85" @default.
• W2892063324 startingPage "78" @default.
• W2892063324 abstract "Therapeutic options for patients with lower-risk myelodysplastic syndrome (MDS) who have failed prior therapies are limited particularly after hypomethylating agent. Several studies have indicated that deregulation of innate immunity signaling is critical in the pathogenesis of MDS. This process involves Toll-like receptor stimulation, cytokine overexpression, and nuclear factor-kB (NF-kB) activation. Since ruxolitinib, a JAK1/JAK2 inhibitor, suppresses NF-kB expression, we conducted a phase 1 dose-escalation study to determine the safety and efficacy of ruxolitinib in previously treated lower-risk MDS patients with evidence of NF-kB activation. Nineteen patients, 8 with chronic myelomonocytic leukemia and 11 with MDS, were enrolled. No dose limiting toxicity was observed and the maximum tolerated dose was 20 mg twice daily. Responses were restricted to MDS patients with an overall response rate of 22% [hematological improvement in platelets (HI-P) = 2, hematological improvement in erythrocytes (HI-E) = 1, partial cytogenetic response (PCyR) = 1]. Of these patients, 2 relapsed (HI-P and PCyR) and 2 continue to be in HI-P and HI-E, respectively, with ongoing therapy. Meaningful improvement in bone marrow dysplasia was only seen in a patient who achieved HI-E. Phosphorylated p65 (pp65) decreased in 6 of 15 patients (40%) including the 2 patients with continued response to treatment and increased in a patient who relapsed after a short-lived HI-P. This suggests potential correlation between reduction in pp65 expression and response duration. In conclusion, ruxolitinib was well-tolerated in previously treated lower-risk MDS patients with evidence of NF-kB activation and resulted in low but significant frequency of responses. (NCT01895842)." @default.
• W2892063324 created "2018-09-27" @default.
• W2892063324 creator A5000750846 @default.
• W2892063324 creator A5005878960 @default.
• W2892063324 creator A5008503600 @default.
• W2892063324 creator A5011595056 @default.
• W2892063324 creator A5012461067 @default.
• W2892063324 creator A5020300580 @default.
• W2892063324 creator A5049385583 @default.
• W2892063324 creator A5055045706 @default.
• W2892063324 creator A5058755419 @default.
• W2892063324 creator A5061026876 @default.
• W2892063324 creator A5069121634 @default.
• W2892063324 creator A5070065917 @default.
• W2892063324 creator A5084290698 @default.
• W2892063324 creator A5085521139 @default.
• W2892063324 creator A5090435894 @default.
• W2892063324 date "2018-10-01" @default.
• W2892063324 modified "2023-10-18" @default.
• W2892063324 title "Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation" @default.
• W2892063324 cites W187238933 @default.
• W2892063324 cites W1928159695 @default.
• W2892063324 cites W1958987550 @default.
• W2892063324 cites W1973465167 @default.
• W2892063324 cites W1991753383 @default.
• W2892063324 cites W1995744610 @default.
• W2892063324 cites W1997757445 @default.
• W2892063324 cites W2006699608 @default.
• W2892063324 cites W2011140047 @default.
• W2892063324 cites W2020719716 @default.
• W2892063324 cites W2022240113 @default.
• W2892063324 cites W2026105799 @default.
• W2892063324 cites W2027584688 @default.
• W2892063324 cites W2029904616 @default.
• W2892063324 cites W2033556677 @default.
• W2892063324 cites W2056583761 @default.
• W2892063324 cites W2071941388 @default.
• W2892063324 cites W2079671946 @default.
• W2892063324 cites W2081279521 @default.
• W2892063324 cites W2086048608 @default.
• W2892063324 cites W2091193918 @default.
• W2892063324 cites W2106584820 @default.
• W2892063324 cites W2114492363 @default.
• W2892063324 cites W2115351357 @default.
• W2892063324 cites W2118771330 @default.
• W2892063324 cites W2121743767 @default.
• W2892063324 cites W2122395736 @default.
• W2892063324 cites W2122761773 @default.
• W2892063324 cites W2123633897 @default.
• W2892063324 cites W2128877614 @default.
• W2892063324 cites W2129510594 @default.
• W2892063324 cites W2131095909 @default.
• W2892063324 cites W2132327973 @default.
• W2892063324 cites W2144770839 @default.
• W2892063324 cites W2158324181 @default.
• W2892063324 cites W2267858353 @default.
• W2892063324 cites W2281556334 @default.
• W2892063324 cites W2326726820 @default.
• W2892063324 cites W2604932078 @default.
• W2892063324 cites W2742767772 @default.
• W2892063324 cites W2780337485 @default.
• W2892063324 cites W4232645703 @default.
• W2892063324 doi "https://doi.org/10.1016/j.leukres.2018.09.004" @default.
• W2892063324 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6750211" @default.
• W2892063324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30245189" @default.
• W2892063324 hasPublicationYear "2018" @default.
• W2892063324 type Work @default.
• W2892063324 sameAs 2892063324 @default.
• W2892063324 citedByCount "9" @default.
• W2892063324 countsByYear W28920633242019 @default.
• W2892063324 countsByYear W28920633242020 @default.
• W2892063324 countsByYear W28920633242021 @default.
• W2892063324 countsByYear W28920633242022 @default.
• W2892063324 countsByYear W28920633242023 @default.
• W2892063324 crossrefType "journal-article" @default.
• W2892063324 hasAuthorship W2892063324A5000750846 @default.
• W2892063324 hasAuthorship W2892063324A5005878960 @default.
• W2892063324 hasAuthorship W2892063324A5008503600 @default.
• W2892063324 hasAuthorship W2892063324A5011595056 @default.
• W2892063324 hasAuthorship W2892063324A5012461067 @default.
• W2892063324 hasAuthorship W2892063324A5020300580 @default.
• W2892063324 hasAuthorship W2892063324A5049385583 @default.
• W2892063324 hasAuthorship W2892063324A5055045706 @default.
• W2892063324 hasAuthorship W2892063324A5058755419 @default.
• W2892063324 hasAuthorship W2892063324A5061026876 @default.
• W2892063324 hasAuthorship W2892063324A5069121634 @default.
• W2892063324 hasAuthorship W2892063324A5070065917 @default.
• W2892063324 hasAuthorship W2892063324A5084290698 @default.
• W2892063324 hasAuthorship W2892063324A5085521139 @default.
• W2892063324 hasAuthorship W2892063324A5090435894 @default.
• W2892063324 hasBestOaLocation W28920633242 @default.
• W2892063324 hasConcept C126322002 @default.
• W2892063324 hasConcept C143998085 @default.
• W2892063324 hasConcept C203014093 @default.
• W2892063324 hasConcept C2776112149 @default.
• W2892063324 hasConcept C2777063308 @default.
• W2892063324 hasConcept C2777928532 @default.
• W2892063324 hasConcept C2780007613 @default.

• next